Daito PharmaceuticalLtd Toekomstige groei
Future criteriumcontroles 2/6
Daito PharmaceuticalLtd is forecast to grow earnings and revenue by 8.8% and 7.1% per annum respectively. EPS is expected to grow by 10.1% per annum. Return on equity is forecast to be 5.6% in 3 years.
Belangrijke informatie
8.8%
Groei van de winst
10.1%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 11.9% |
| Inkomstengroei | 7.1% |
| Toekomstig rendement op eigen vermogen | 5.6% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 23 Jul 2024 |
Recente toekomstige groei-updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 5/31/2027 | 57,500 | 3,870 | 3,570 | N/A | 1 |
| 5/31/2026 | 53,000 | 3,300 | 2,400 | N/A | 1 |
| 5/31/2025 | 49,500 | 2,710 | 310 | N/A | 1 |
| 8/31/2024 | 47,395 | 3,230 | N/A | N/A | N/A |
| 5/31/2024 | 46,895 | 3,295 | -1,094 | 5,182 | N/A |
| 2/29/2024 | 45,193 | 3,279 | N/A | N/A | N/A |
| 11/30/2023 | 45,844 | 3,390 | -2,689 | 4,960 | N/A |
| 8/31/2023 | 45,238 | 3,337 | N/A | N/A | N/A |
| 5/31/2023 | 45,101 | 3,600 | -1,401 | 4,155 | N/A |
| 2/28/2023 | 44,451 | 3,350 | N/A | N/A | N/A |
| 11/30/2022 | 44,368 | 3,653 | -1,619 | 3,104 | N/A |
| 8/31/2022 | 43,759 | 3,789 | N/A | N/A | N/A |
| 5/31/2022 | 43,464 | 4,668 | -363 | 4,370 | N/A |
| 2/28/2022 | 44,462 | 4,525 | N/A | N/A | N/A |
| 11/30/2021 | 45,142 | 4,600 | 221 | 5,870 | N/A |
| 8/31/2021 | 46,757 | 4,750 | N/A | N/A | N/A |
| 5/31/2021 | 48,714 | 4,246 | -1,167 | 5,182 | N/A |
| 2/28/2021 | 48,454 | 4,402 | N/A | N/A | N/A |
| 11/30/2020 | 47,773 | 4,365 | -543 | 3,455 | N/A |
| 8/31/2020 | 47,036 | 4,345 | N/A | N/A | N/A |
| 5/31/2020 | 44,991 | 3,944 | 1,533 | 4,306 | N/A |
| 2/29/2020 | 45,105 | 4,204 | N/A | N/A | N/A |
| 11/30/2019 | 44,242 | 3,842 | 4,520 | 7,481 | N/A |
| 8/31/2019 | 43,053 | 3,654 | N/A | N/A | N/A |
| 5/31/2019 | 41,134 | 3,513 | 3,226 | 6,888 | N/A |
| 2/28/2019 | 40,640 | 3,291 | N/A | N/A | N/A |
| 11/30/2018 | 39,566 | 3,127 | 2,215 | 5,829 | N/A |
| 8/31/2018 | 39,933 | 3,147 | N/A | N/A | N/A |
| 5/31/2018 | 39,875 | 3,041 | N/A | 5,465 | N/A |
| 2/28/2018 | 39,701 | 2,913 | N/A | N/A | N/A |
| 11/30/2017 | 39,219 | 2,820 | N/A | 4,539 | N/A |
| 8/31/2017 | 38,554 | 2,658 | N/A | N/A | N/A |
| 5/31/2017 | 37,984 | 2,656 | N/A | 5,069 | N/A |
| 2/28/2017 | 37,283 | 2,698 | N/A | N/A | N/A |
| 11/30/2016 | 37,270 | 2,722 | N/A | 3,385 | N/A |
| 8/31/2016 | 36,747 | 2,559 | N/A | N/A | N/A |
| 5/31/2016 | 36,370 | 2,566 | N/A | 2,948 | N/A |
| 2/29/2016 | 36,416 | 2,639 | N/A | N/A | N/A |
| 11/30/2015 | 35,691 | 2,403 | N/A | 3,252 | N/A |
| 8/31/2015 | 35,370 | 2,468 | N/A | N/A | N/A |
| 5/31/2015 | 34,058 | 2,246 | N/A | 3,739 | N/A |
| 2/28/2015 | 33,765 | 2,080 | N/A | N/A | N/A |
| 11/30/2014 | 32,528 | 2,010 | N/A | 3,709 | N/A |
| 8/31/2014 | 31,560 | 1,864 | N/A | N/A | N/A |
| 5/31/2014 | 31,196 | 1,811 | N/A | 2,744 | N/A |
| 2/28/2014 | 29,876 | 1,910 | N/A | N/A | N/A |
| 11/30/2013 | 29,680 | 1,787 | N/A | 2,990 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 4577's forecast earnings growth (8.8% per year) is above the savings rate (0.3%).
Winst versus markt: 4577's earnings (8.8% per year) are forecast to grow slower than the JP market (8.9% per year).
Hoge groeiwinsten: 4577's earnings are forecast to grow, but not significantly.
Omzet versus markt: 4577's revenue (7.1% per year) is forecast to grow faster than the JP market (4.2% per year).
Hoge groei-inkomsten: 4577's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 4577's Return on Equity is forecast to be low in 3 years time (5.6%).